TBC1 domain family member 3 pseudogene 6Genealiases: []
Q-omics provides the consensus-scored TBC1D3P6 profile across patient tissues and cancer cell-line models. TBC1D3P6 expression is associated with patient survival in 5 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, TBC1D3P6 is differentially expressed in 2, with the highest sampling consensus in LUSC. Additionally, TBC1D3P6 RNA expression shows 6,155 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight BRCA, LUSC, and STAD as cancer lineages where TBC1D3P6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TBC1D3P6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TBC1D3P6 survival associations across molecular data types. TBC1D3P6 RNA expression shows survival associations in the most cancer types (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TBC1D3P6 RNA expression–survival associations across cancer types. High TBC1D3P6 expression shows unfavorable associations in BRCA, STAD, THYM and KICH, but favorable associations in CESC. The BRCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for TBC1D3P6 RNA expression.
This table summarizes TBC1D3P6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for TBC1D3P6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TBC1D3P6 shows higher tumor expression in LUSC and BRCA. The LUSC box plot shows higher TBC1D3P6 RNA expression in tumor versus normal tissue (log2 FC = +0.012, t-test p = .024).
This table shows molecular features associated with TBC1D3P6 in patient tissues and cancer cell lines. In patient samples, TBC1D3P6 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
